Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Stage/Subtype:  recurrent renal cell cancer
Trial Type:  Treatment
Results 1-25 of 71 for your search:
Start Over
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AV-951-15-303, NCI-2016-00282, NCT02627963
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-426, NCI-2016-01738, 163460, 2016-000588-17, NCT02853331
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Stereotactic Radiosurgery in Treating Patients with Kidney Tumors Who Are Poor Candidates for Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 12806, NCI-2010-01064, NCT00458484
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA223-001, NCI-2014-00201, NCT01714739
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-029, NCI-2014-01328, 2013-004072-36, NCT02089685
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7080-A001-111, NCI-2016-00529, NCT02501096
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: X4P-001-RCCA, NCI-2016-00531, NCT02667886
An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCAGN 1876-101, NCI-2016-01221, NCT02697591
Anti-CD70 Peripheral Blood Lymphocytes in Treating Patients with CD70 Expressing Solid Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 16-C-0131, NCI-2016-01030, NCT02830724
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX014-01, NCI-2016-01448, NCT02837991
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCAGN 1949-101, NCI-2016-01704, NCT02923349
Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: X4P-001-RCCB, NCI-2016-01920, NCT02923531
Sitravatinib and Nivolumab in Treating Patients with Advanced or Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0332, NCI-2017-00324, NCT03015740
Axitinib and Nivolumab in Treating Patients with Advanced Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: GU-102, NCI-2017-01090, NCT03172754
Aldesleukin and Nivolumab in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2016.103, NCI-2017-01121, NCT02989714
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy and Pembrolizumab in Treating Patients with Metastatic Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, 306343, P09567, NCT01174121
Pidilizumab with or without Vaccine Therapy in Treating Patients with Stage IV Kidney Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-178, NCI-2012-00259, NCT01441765
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1152, NCI-2012-02027, NCT01767636
Start Over